Eli Lilly and Company (LLY) Comparison with companies in other sectors?

Eli Lilly and Company has a share price of 947.74M. You can analyze Eli Lilly and Company (LLY) competitors across different market sectors through stock heatmaps.

What are LLY's NET and operating margins?

Eli Lilly and Company (LLY) operating margin is around 0.41, and net profit margin is approximately 0.23 as of the latest reports.

In what way does LLY's earnings per share (EPS) trend reflect its financial momentum?

Eli Lilly and Company (LLY) EPS is 12.25 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Eli Lilly and Company is 63.09, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Eli Lilly and Company?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Eli Lilly and Company like P/E which is 62.32, P/B which is 43.90, and PEG which is 12.61. Compare them with sector averages to evaluate if the stock is priced fairly.

Eli Lilly and Company

LLY•NYSE

Healthcare

Drug Manufacturers - General

$772.81

$-7.64(-0.98%)

Fundamental Analysis of Eli Lilly and Company (LLY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$12.25

P/E Ratio

63.09

ROE

0.77%

Net Margin

0.23%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$732.42B

Shares OutstandingTotal number of shares issued

$947.74M

Book Value/ShareNet worth per share

$17.63

Revenue/ShareAnnual revenue per share

$54.53

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$12.25

Net MarginNet income as percentage of revenue

22.66%

Operating MarginOperating income as percentage of revenue

40.70%

ROEReturn on shareholders' equity

76.92%

ROAReturn on total assets

12.42%

ROCEReturn on capital employed

33.62%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.54

Cash/ShareCash and equivalents per share

$3.58

FCF YieldFree cash flow as percentage of market cap

0.07%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$5.60

Dividend YieldAnnual dividend as percentage of stock price

0.73%

Financial Ratios Analysis data is not available for LLYFinancial Ratios Analysis details for LLY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for LLYSector Benchmarking details for LLY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Eli Lilly and Company Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Eli Lilly and Company. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Eli Lilly and Company's unique business strengths and challenges.

Key Financial Metrics for Eli Lilly and Company

For Eli Lilly and Company, essential financial indicators include EPS 12.25, PE 63.09, and ROE 0.77. These key ratios reveal insights into Eli Lilly and Company's profitability, valuation, and operational health. Understanding these metrics enables you to compare Eli Lilly and Company with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Eli Lilly and Company

Metrics like Net Margin 22.66% and ROA 12.42% shed light on how well Eli Lilly and Company is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Eli Lilly and Company can sustain its operations and continue growing in the future.

Valuation and Market Position of Eli Lilly and Company

Using ratios such as P/B Ratio 43.90 and PEG Ratio 12.61, investors can assess whether Eli Lilly and Company is appropriately valued based on its financials and growth potential. These figures, combined with Eli Lilly and Company's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Eli Lilly and Company

Financial health indicators, such as Debt/Equity Ratio 2.44 and Cash Flow $0.54, provide a snapshot of Eli Lilly and Company's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Eli Lilly and Company, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Eli Lilly and Company

Investing in Eli Lilly and Company based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Eli Lilly and Company focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;